WO1994002610A1
(en)
*
|
1992-07-17 |
1994-02-03 |
Dana-Farber Cancer Institute |
Method of intracellular binding of target molecules
|
AU5128593A
(en)
*
|
1992-09-16 |
1994-04-12 |
University Of Tennessee Research Corporation, The |
Antigen of hybrid m protein and carrier for group a streptococcal vaccine
|
FR2706486B1
(fr)
*
|
1993-06-16 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
|
JPH09500902A
(ja)
*
|
1993-07-30 |
1997-01-28 |
トーマス・ジェファーソン・ユニバーシティ |
細胞内免疫感作
|
AU1925195A
(en)
|
1994-02-22 |
1995-09-04 |
Dana-Farber Cancer Institute |
Nucleic acid delivery system, method of synthesis and uses thereof
|
US7083979B1
(en)
|
1994-03-25 |
2006-08-01 |
Indiana University Foundation |
Methods for enhanced retroviral-mediated gene transfer
|
US5686278A
(en)
*
|
1994-03-25 |
1997-11-11 |
Indiana University Foundation |
Methods for enhanced retrovirus-mediated gene transfer
|
US5910486A
(en)
*
|
1994-09-06 |
1999-06-08 |
Uab Research Foundation |
Methods for modulating protein function in cells using, intracellular antibody homologues
|
US6451995B1
(en)
*
|
1996-03-20 |
2002-09-17 |
Sloan-Kettering Institute For Cancer Research |
Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
|
EP0934083B1
(de)
*
|
1996-10-23 |
2009-04-29 |
The Trustees Of The University Of Pennsylvania |
Verbesserte impfstoffe
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
SK287687B6
(sk)
|
1996-12-06 |
2011-06-06 |
Aventis Pharmaceuticals Inc. |
Izolovaný polypeptid kódovaný génom podobným génu pre lipázu, prostriedok majúci fosfolipázovú účinnosť, farmaceutický prostriedok, antigénny fragment a izolovaná nukleová kyselina, biologicky aktívny prostriedok, vektor, rekombinovaná hostiteľská bunka, prostriedok využiteľný na transfekáciu cieľovej bunky, spôsob výroby polypeptidu a polypeptid takto vyrobený, protilátka, hybridomná bunka, spôsob in vitro sceeningu, spôsob in vitro enzymatickej hydrolýzy, použitie polypeptidu a protilátky a
|
WO1999014353A2
(en)
*
|
1997-09-19 |
1999-03-25 |
Dana-Farber Cancer Institute, Inc. |
Intrabody-mediated control of immune reactions
|
US6077676A
(en)
*
|
1997-12-18 |
2000-06-20 |
Spectral Diagnostics, Inc. |
Single-chain polypeptides comprising troponin I and troponin C
|
CA2316808C
(en)
|
1998-01-08 |
2007-04-10 |
Aventis Pharmaceuticals Products Inc. |
Transgenic rabbit that expresses a functional human lipoprotein (a)
|
PT1210428E
(pt)
|
1999-08-23 |
2015-07-21 |
Genetics Inst Llc |
Pd-1, um recetor para b7-4 e suas utilizações
|
US7265095B1
(en)
*
|
1999-09-20 |
2007-09-04 |
Aberdeen University |
Monoclonal antibody 3F1H10 neutralising VHSV (viral haemorrhagic septicaemia virus)
|
US20030049251A1
(en)
*
|
1999-12-08 |
2003-03-13 |
Barbas Carlos F. |
Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
|
US7078486B2
(en)
|
1999-12-10 |
2006-07-18 |
Spectral Diagnostics, Inc. |
Single-chain polypeptides comprising troponin I and troponin C
|
JP2003518942A
(ja)
|
1999-12-30 |
2003-06-17 |
プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
肝細胞成長、形質細胞分化、又はt細胞サブセットの活性を、xbp−1活性の変調により変調することに関する方法及び組成物
|
US6291652B1
(en)
|
2000-01-07 |
2001-09-18 |
The Regents Of The University Of California |
Antibodies specific for proteins having polyglutamine expansions
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
DK1290023T3
(da)
|
2000-03-31 |
2011-02-14 |
Aventis Pharma Inc |
Nuklearfaktor KB inducerende faktor
|
AU2001262960A1
(en)
*
|
2000-04-28 |
2001-11-12 |
Zengen, Inc. |
New antibodies to biological membranes
|
US6410246B1
(en)
|
2000-06-23 |
2002-06-25 |
Genetastix Corporation |
Highly diverse library of yeast expression vectors
|
US6410271B1
(en)
|
2000-06-23 |
2002-06-25 |
Genetastix Corporation |
Generation of highly diverse library of expression vectors via homologous recombination in yeast
|
US6406863B1
(en)
*
|
2000-06-23 |
2002-06-18 |
Genetastix Corporation |
High throughput generation and screening of fully human antibody repertoire in yeast
|
US7083945B1
(en)
*
|
2000-10-27 |
2006-08-01 |
The Board Of Regents Of The University Of Texas System |
Isolation of binding proteins with high affinity to ligands
|
AU2002338446A1
(en)
*
|
2001-01-23 |
2002-11-05 |
University Of Rochester Medical Center |
Methods of producing or identifying intrabodies in eukaryotic cells
|
CA2442066C
(en)
|
2001-04-02 |
2005-11-01 |
Wyeth |
Pd-1, a receptor for b7-4, and uses therefor
|
US7247618B2
(en)
*
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
JP4423542B2
(ja)
|
2002-04-25 |
2010-03-03 |
東亞合成株式会社 |
抗菌性ポリペプチド及びその利用
|
AU2003239966B9
(en)
*
|
2002-06-03 |
2010-08-26 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
EP1523496B1
(de)
|
2002-07-18 |
2011-06-29 |
Merus B.V. |
Rekombinante Produktion von Antikörpermischungen
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
US20040067532A1
(en)
*
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
EP1585767A2
(de)
*
|
2003-01-16 |
2005-10-19 |
Genentech, Inc. |
Phagenbibliothek von synthetischen antikörpern
|
JP5052893B2
(ja)
|
2003-02-20 |
2012-10-17 |
アメリカ合衆国 |
ポックスベクターにおける新規の挿入部位
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
WO2005012531A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Genentech, Inc. |
Antibody cdr polypeptide sequences with restricted diversity
|
EP1688486B1
(de)
|
2003-10-29 |
2016-12-14 |
Toagosei Co., Ltd. |
Antibakterielles peptid und seine nutzung
|
JP5912211B2
(ja)
|
2004-01-20 |
2016-04-27 |
メルス ビー.ヴィー. |
結合タンパク質の混合物
|
US7785903B2
(en)
*
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
JP4507080B2
(ja)
|
2004-07-30 |
2010-07-21 |
東亞合成株式会社 |
抗菌ペプチド及びその利用
|
WO2006040153A2
(en)
*
|
2004-10-13 |
2006-04-20 |
Ablynx N.V. |
Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
|
US20060121042A1
(en)
|
2004-10-27 |
2006-06-08 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
US20060147997A1
(en)
*
|
2004-11-30 |
2006-07-06 |
Virosys Pharmaceuticals, Inc. |
PenetraBodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
|
JP4730584B2
(ja)
|
2004-12-06 |
2011-07-20 |
東亞合成株式会社 |
抗菌ペプチド及びその利用
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
SG184709A1
(en)
|
2005-05-18 |
2012-10-30 |
Ablynx Nv |
Improved nanobodies™ against tumor necrosis factor-alpha
|
CA2960105A1
(en)
|
2005-05-20 |
2006-11-23 |
Ablynx Nv |
Single domain vhh antibodies against von willebrand factor
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
US9133267B2
(en)
|
2005-11-22 |
2015-09-15 |
The Trustees Of The University Of Pennsylvania |
Antibody treatment of Alzheimer's and related diseases
|
EP1973951A2
(de)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Bindende polypeptide mit eingeschränkten diversitätssequenzen
|
ES2535856T3
(es)
|
2005-12-15 |
2015-05-18 |
Genentech, Inc. |
Métodos y composiciones para dirigirse a la poliubiquitina
|
GB0605584D0
(en)
*
|
2006-03-20 |
2006-04-26 |
Olink Ab |
Method for analyte detection using proximity probes
|
WO2007134050A2
(en)
*
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
JP2009543862A
(ja)
|
2006-07-14 |
2009-12-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ガンのバイオマーカーおよびその使用方法
|
WO2008074839A2
(en)
|
2006-12-19 |
2008-06-26 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
WO2008074840A2
(en)
|
2006-12-19 |
2008-06-26 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
|
US8828665B2
(en)
|
2007-02-16 |
2014-09-09 |
Ark Diagnostics, Inc. |
Compounds and methods for use in detecting gabapentin
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
EP3753947A1
(de)
|
2007-09-14 |
2020-12-23 |
Adimab, LLC |
Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon
|
NZ586611A
(en)
|
2007-12-06 |
2012-09-28 |
Dana Farber Cancer Inst Inc |
Antibodies against influenza virus and methods of use thereof
|
EP2947097A1
(de)
|
2008-04-07 |
2015-11-25 |
Ablynx N.V. |
Gegen Notch-Signalwege gerichtete Aminosäuresequenzen und Verwendungen davon
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
AU2009298879A1
(en)
|
2008-09-23 |
2010-04-08 |
President And Fellows Of Harvard College |
SIRT4 and uses thereof
|
KR102097887B1
(ko)
|
2008-09-26 |
2020-04-06 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도
|
CN102215875B
(zh)
*
|
2008-10-16 |
2014-08-06 |
凯瑟琳·科根·法瑞纳斯 |
持续药物递送系统
|
AU2009308293B2
(en)
|
2008-10-22 |
2015-02-05 |
Genentech, Inc. |
Modulation of axon degeneration
|
EP2349335B1
(de)
|
2008-10-24 |
2013-08-07 |
ARK Diagnostics, Inc. |
Levetiracetam-immunoassays
|
EP2353005B1
(de)
|
2008-12-01 |
2018-10-03 |
The Board of Trustees of The Leland Stanford Junior University |
Verfahren und zusammensetzungen zur erkennung komplementbindender antikörper
|
US9599591B2
(en)
|
2009-03-06 |
2017-03-21 |
California Institute Of Technology |
Low cost, portable sensor for molecular assays
|
EP2414542B1
(de)
|
2009-03-30 |
2017-08-30 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Verfahren zur vorhersage des klinischen verlaufs und behandlung von multipler sklerose
|
WO2010115998A2
(en)
|
2009-04-10 |
2010-10-14 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
WO2010129033A2
(en)
*
|
2009-04-29 |
2010-11-11 |
Calmune Corporation |
Modified antibodies for passive immunotherapy
|
CA2764398A1
(en)
|
2009-06-05 |
2010-12-09 |
Erik Depla |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
ES2599076T3
(es)
|
2009-09-02 |
2017-01-31 |
Genentech, Inc. |
Smoothened mutante y métodos de utilización del mismo
|
EP2483407A2
(de)
|
2009-09-30 |
2012-08-08 |
President and Fellows of Harvard College |
Verfahren zur autophagie-modulation durch modulation autophagie-verstärkender genprodukte
|
CN104043126A
(zh)
|
2009-10-22 |
2014-09-17 |
霍夫曼-拉罗奇有限公司 |
轴突变性的调节
|
EP2496243A2
(de)
|
2009-11-04 |
2012-09-12 |
Erasmus University Medical Center Rotterdam |
Neuartige verbindungen zur modulierung der gefässneubildung und behandlungsverfahren mit diesen verbindungen
|
US8968740B2
(en)
|
2009-11-13 |
2015-03-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US8962807B2
(en)
|
2009-12-14 |
2015-02-24 |
Ablynx N.V. |
Single variable domain antibodies against OX40L, constructs and therapeutic use
|
CA2784385A1
(en)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
WO2011083140A1
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4
|
WO2011085178A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Trustees Of Dartmouth College |
Monomeric bi-specific fusion protein
|
US9745589B2
(en)
|
2010-01-14 |
2017-08-29 |
Cornell University |
Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
GB201004292D0
(en)
*
|
2010-03-15 |
2010-04-28 |
Olink Ab |
Assay for localised detection of analytes
|
WO2011119920A2
(en)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
RU2012148398A
(ru)
|
2010-04-18 |
2014-05-27 |
Иеда Рисеч Энд Девелопмент Ко. Лтд. |
МОЛЕКУЛЫ И СПОСОБЫ ПРИМЕНЕНИЯ МОЛЕКУЛ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНЕЙ, АССОЦИИРОВАННЫХ С ErbB/ErbB ЛИГАНДАМИ
|
EP3508854A1
(de)
|
2010-04-27 |
2019-07-10 |
The Regents of The University of California |
Krebsbiomarker und verfahren zur verwendung davon
|
CN103068378B
(zh)
|
2010-05-10 |
2016-07-06 |
中央研究院 |
具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
|
BR112012029588A2
(pt)
|
2010-05-20 |
2017-07-25 |
Ablynx Nv |
materiais biológicas relacionados a her3.
|
GB201011971D0
(en)
|
2010-07-15 |
2010-09-01 |
Olink Ab |
Methods and product
|
US9354228B2
(en)
|
2010-07-16 |
2016-05-31 |
Adimab, Llc |
Antibody libraries
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
US10669569B2
(en)
|
2010-10-15 |
2020-06-02 |
Navinci Diagnostics Ab |
Dynamic range methods
|
KR101650995B1
(ko)
|
2010-11-08 |
2016-08-25 |
노파르티스 아게 |
Cxcr2 결합 폴리펩티드
|
EP2466310A1
(de)
|
2010-12-17 |
2012-06-20 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH |
Mittel und Verfahren für den Nachweis von mehrstrangigen Brüchen
|
GB201101621D0
(en)
|
2011-01-31 |
2011-03-16 |
Olink Ab |
Method and product
|
WO2012109238A2
(en)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Methods for increasing immune responses using agents that directly bind to and activate ire-1
|
EP2673297A2
(de)
|
2011-02-11 |
2013-12-18 |
Zyngenia, Inc. |
Monovalente und multivalente multispezifische komplexe und verwendungen davon
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
GB201107863D0
(en)
|
2011-05-11 |
2011-06-22 |
Olink Ab |
Method and product
|
CA2832109C
(en)
|
2011-06-10 |
2021-07-06 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
WO2012175740A1
(en)
|
2011-06-23 |
2012-12-27 |
Ablynx Nv |
Immunoglobulin single variable domains directed against ige
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
EP2586461A1
(de)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Von einem eingehüllten Virus abgeleitete Virenpartikel
|
GB201201547D0
(en)
|
2012-01-30 |
2012-03-14 |
Olink Ab |
Method and product
|
WO2013134774A1
(en)
|
2012-03-09 |
2013-09-12 |
Cornell University |
Modulation of breast cancer growth by modulation of xbp1 activity
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
SG10201607371UA
(en)
|
2012-04-20 |
2016-10-28 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
AU2013266243A1
(en)
|
2012-05-24 |
2014-12-18 |
Beth Israel Deaconess Medical Center, Inc. |
Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
SG10201605703TA
(en)
|
2012-07-06 |
2016-09-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
US20150285802A1
(en)
|
2012-07-18 |
2015-10-08 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating, preventing and predicting risk of developing breast cancer
|
WO2014022759A1
(en)
|
2012-08-03 |
2014-02-06 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
WO2014031762A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
CN104918637B
(zh)
*
|
2012-12-05 |
2018-12-11 |
生控基因疫苗股份有限公司 |
用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
WO2014113717A1
(en)
|
2013-01-18 |
2014-07-24 |
Ark Diagnostics, Inc. |
Voriconazole immunoassays
|
WO2014126861A1
(en)
|
2013-02-13 |
2014-08-21 |
Ark Diagnostics, Inc. |
Posaconazole immunoassays
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
WO2014139980A1
(en)
|
2013-03-12 |
2014-09-18 |
Ventana Medical Systems, Inc. |
Proximity assay for in situ detection of targets
|
WO2014139979A1
(en)
|
2013-03-12 |
2014-09-18 |
Ventana Medical Systems, Inc. |
Quantum dot in situ hybridization
|
EP2972348B1
(de)
|
2013-03-14 |
2018-08-15 |
The Board of Trustees of The Leland Stanford Junior University |
Verfahren zum nachweis donatorspezifischer antikörper
|
WO2014197369A1
(en)
|
2013-06-06 |
2014-12-11 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
|
CN105636984A
(zh)
|
2013-06-13 |
2016-06-01 |
法斯特弗沃德制药有限公司 |
用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物,该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
WO2015017529A2
(en)
|
2013-07-31 |
2015-02-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
|
MX2016002643A
(es)
|
2013-08-29 |
2016-10-04 |
|
Conjugados de penetracion celular y metodos de uso de estos.
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
CA2923579C
(en)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
EP3521431A1
(de)
|
2013-09-25 |
2019-08-07 |
Cornell University |
Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
|
EP3757130A1
(de)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Verfahren zur behandlung von blutkrebs
|
EP2873423B1
(de)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
TW201620939A
(zh)
|
2014-01-16 |
2016-06-16 |
中央研究院 |
治療及檢測癌症之組合物及方法
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
US10350264B2
(en)
|
2014-03-27 |
2019-07-16 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
|
JP6562942B2
(ja)
|
2014-03-27 |
2019-08-28 |
アカデミア シニカAcademia Sinica |
反応性標識化合物およびその使用
|
AU2015267045B2
(en)
|
2014-05-27 |
2021-02-25 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカAcademia Sinica |
抗cd20糖操作抗体群およびその使用
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
WO2015184008A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
CN107001442B
(zh)
|
2014-07-15 |
2021-04-27 |
耶路撒冷希伯来大学伊森姆研究发展公司 |
Cd44的分离的多肽及其应用
|
US20170275366A1
(en)
*
|
2014-07-29 |
2017-09-28 |
Pfizer Inc. |
EGFRvIII Specific Chimeric Antigen Receptor For Cancer Immunotherapy
|
CA2960712A1
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
Human inkt cell activation using glycolipids
|
US20180072815A1
(en)
|
2014-10-23 |
2018-03-15 |
Singh Biotechnology, Llc |
Single Domain Antibodies Directed Against Intracellular Antigens
|
BR122020006907B8
(pt)
*
|
2014-10-23 |
2023-01-31 |
Singh Biotechnology Llc |
Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
|
SG11201703667SA
(en)
|
2014-11-05 |
2017-06-29 |
Annexon Inc |
Humanized anti-complement factor c1q antibodies and uses thereof
|
WO2016079736A2
(en)
|
2014-11-17 |
2016-05-26 |
Yeda Research And Development Co. Ltd. |
Methods of treating diseases related to mitochondrial function
|
EP3227687A4
(de)
|
2014-12-05 |
2018-10-24 |
Prelude, Inc. |
Dcis-wiederauftreten und invasiver brustkrebs
|
US11220545B2
(en)
|
2014-12-08 |
2022-01-11 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
JP6779887B2
(ja)
|
2015-01-24 |
2020-11-04 |
アカデミア シニカAcademia Sinica |
新規なグリカンコンジュゲートおよびその使用方法
|
AU2016209056B2
(en)
|
2015-01-24 |
2021-01-28 |
Academia Sinica |
Cancer markers and methods of use thereof
|
KR102620346B1
(ko)
|
2015-01-30 |
2024-01-02 |
아카데미아 시니카 |
증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
US9958464B2
(en)
|
2015-03-03 |
2018-05-01 |
Ark Diagnostics, Inc. |
Pregabalin immunoassays
|
EP3735982A1
(de)
|
2015-03-10 |
2020-11-11 |
The University of Massachusetts |
Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
|
IL237852A0
(en)
|
2015-03-19 |
2016-03-24 |
Yeda Res & Dev |
Antibodies against amphigoline, medical preparations containing them and their use
|
EP3069730A3
(de)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
EP3294280A1
(de)
|
2015-05-11 |
2018-03-21 |
Yeda Research and Development Co., Ltd. |
Citrinhemmer zur behandlung von krebs
|
AU2016260909B2
(en)
|
2015-05-13 |
2019-08-22 |
Ablynx N.V. |
T cell recruiting polypeptides based on CD3 reactivity
|
LT3294768T
(lt)
|
2015-05-13 |
2019-11-11 |
Ablynx Nv |
T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
|
US10935544B2
(en)
|
2015-09-04 |
2021-03-02 |
Obi Pharma, Inc. |
Glycan arrays and method of use
|
EP3362074B1
(de)
|
2015-10-16 |
2023-08-09 |
President and Fellows of Harvard College |
Pd-1-modulation in regulatorischen t-zellen zur regulierung von t-zelleffektorimmunreaktionen
|
TWI746473B
(zh)
|
2015-11-02 |
2021-11-21 |
美商辛分子醫藥有限公司 |
針對細胞內抗原之單域抗體
|
US10527613B2
(en)
|
2015-11-10 |
2020-01-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Biomarker detection methods and systems and kits for practicing same
|
WO2017122203A1
(en)
|
2016-01-11 |
2017-07-20 |
Technion Research & Development Foundation Limited |
Methods of determining prognosis of sepsis and treating same
|
UA125252C2
(uk)
|
2016-01-21 |
2022-02-09 |
Пфайзер Інк. |
Химерний антигенний рецептор, що націлений на варіант iii рецептора епідермального фактора росту
|
TW201936640A
(zh)
|
2016-01-21 |
2019-09-16 |
美商輝瑞股份有限公司 |
對表皮生長因子受體變異體iii具特異性之抗體類及彼等之用途
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
EP4043492A1
(de)
|
2016-03-01 |
2022-08-17 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Gegen humanen poliovirus-rezeptor (pvr) spezifische antikörper
|
CN109195996A
(zh)
|
2016-03-08 |
2019-01-11 |
中央研究院 |
N-聚醣及其阵列的模组化合成方法
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
CN109311995A
(zh)
|
2016-03-29 |
2019-02-05 |
台湾浩鼎生技股份有限公司 |
抗体、药物组合物和方法
|
BR112018071683A2
(pt)
|
2016-04-22 |
2019-02-19 |
Obi Pharma, Inc. |
método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
|
CN106267409B
(zh)
*
|
2016-07-01 |
2019-02-01 |
翁炳焕 |
艾滋病生物治疗反应器
|
CN106178163B
(zh)
*
|
2016-07-01 |
2019-02-01 |
翁炳焕 |
艾滋病生物细胞免疫治疗仪
|
KR20230117482A
(ko)
|
2016-07-27 |
2023-08-08 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
KR102528998B1
(ko)
|
2016-07-29 |
2023-05-03 |
오비아이 파머 인코퍼레이티드 |
인간 항체, 제약 조성물 및 방법
|
IL247368A0
(en)
|
2016-08-18 |
2016-11-30 |
Yeda Res & Dev |
Diagnostic and therapeutic uses of exosomes
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
CA3034643A1
(en)
|
2016-09-20 |
2018-03-29 |
Ellen Weisberg |
Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
|
US11840569B2
(en)
|
2016-11-16 |
2023-12-12 |
Ablynx N.V. |
T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
|
KR20190077103A
(ko)
|
2016-11-21 |
2019-07-02 |
오비아이 파머 인코퍼레이티드 |
접합된 생물학적 분자, 제약 조성물 및 방법
|
IL252151A0
(en)
|
2017-05-07 |
2017-07-31 |
Fainzilber Michael |
Treatment of stress disorders
|
EP3634991A1
(de)
|
2017-05-23 |
2020-04-15 |
Technion Research & Development Foundation Limited |
Mittel zur hemmung von gads-dimerisierung und verfahren zur verwendung davon
|
US11820822B2
(en)
|
2017-06-06 |
2023-11-21 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
|
JP2021501587A
(ja)
*
|
2017-11-03 |
2021-01-21 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Cd38指向性キメラ抗原受容体構築物
|
WO2019195549A1
(en)
*
|
2018-04-04 |
2019-10-10 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for engineered assembly activating proteins (eaaps)
|
JPWO2019235581A1
(ja)
|
2018-06-06 |
2021-07-08 |
国立大学法人大阪大学 |
Regnase−1が関与する疾患の治療および/または予防方法
|
WO2019238944A1
(en)
|
2018-06-15 |
2019-12-19 |
Olink Proteomics Ab |
Biomarker panel for ovarian cancer
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
AU2019339508A1
(en)
|
2018-09-14 |
2021-04-15 |
Prelude Corporation |
Method of selection for treatment of subjects at risk of invasive breast cancer
|
US20220033519A1
(en)
*
|
2018-09-21 |
2022-02-03 |
National Research Council Of Canada |
Intrabodies for reducing fut8 activity
|
WO2020245663A1
(en)
|
2019-06-01 |
2020-12-10 |
Institut Pasteur |
Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
|
IL268111A
(en)
|
2019-07-16 |
2021-01-31 |
Fainzilber Michael |
Methods of treating pain
|
EP4096647A1
(de)
|
2020-01-30 |
2022-12-07 |
Yeda Research and Development Co. Ltd |
Behandlung einer akuten lebererkrankung mit tlr-mik-inhibitoren
|
IL279559A
(en)
|
2020-12-17 |
2022-07-01 |
Yeda Res & Dev |
Controlling the ubiquitination process of mlkl for disease treatment
|
WO2022159793A2
(en)
|
2021-01-25 |
2022-07-28 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for identifying neuroendocrine prostate cancer
|
CA3210477A1
(en)
|
2021-02-11 |
2022-08-18 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancers using sting agonists
|
EP4294834A2
(de)
|
2021-02-19 |
2023-12-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Einzeldomänenantikörper zur neutralisierung von sars-cov-2
|
KR20230165212A
(ko)
|
2021-03-02 |
2023-12-05 |
다나-파버 캔서 인스티튜트 인크. |
적혈구 장애의 치료 방법
|
EP4319800A1
(de)
|
2021-04-07 |
2024-02-14 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
WO2023091704A1
(en)
|
2021-11-18 |
2023-05-25 |
Circularis Biotechnologies, Inc. |
Compositions and methods for production of circular nucleic acid molecules
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2024023271A1
(en)
|
2022-07-27 |
2024-02-01 |
Ablynx Nv |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|